Brief: Propanc Biopharma submits orphan drug designation request to FDA for treatment of ovarian cancer
25/10/2017 13:29
Oct 25 (Reuters) - Propanc Biopharma Inc PPCB.PK -
* Propanc Biopharma submits orphan drug designation request
to the US Food And Drug Administration for treatment of ovarian
cancer
Source text for Eikon: ID:nMKWykCqda
Further company coverage: PPCB.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Propanc Biopharma
See all newsNASDAQ TRADE HALT HALT NEWS PENDING AT 09:29 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
Brief: Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock - SEC Filing
Brief: Propanc Biopharma To File Cta In Australia For Phase 1B Study In 30–40 Advanced Cancer Patients